Bioanalysis of Antibody-Drug Conjugates (ADCs) Workshop
March 13, 2026
Spring House Innovation Park, PA
An IQ In-person Workshop
Click here to register. [Registration closes on March 6th, see below.]
LIMITED IN-PERSON REGISTRATION
In-person registration is limited. Please be sure to register early to secure your spot. In-person registration will close when the room capacity has been reached. [If the workshop is at in-person capacity, you will be able to join a waiting list.]
REGISTRATION CLOSING
The Registration site will close at 4 pm ET on Friday, March 6, 2026. If you wish to register after that date, please contact the IQ Secretariat prior to the Workshop start on March 13, 2026 to make the appropriate arrangements. Late inquiries may result in delayed access to the start of the event.
DATE/TIME
Friday, March 13, 2026
Approx. 8 AM – 4 PM ET
IN-PERSON EVENT
This Workshop will be in-person only.
WORKSHOP MATERIALS
Download our Workshop 1-pager and share with your interested colleagues.
A draft program is available here (as of 2/26/26).
REGISTRATION AND FEES **Registration is now open**
Cost: $100 USD
Note: This nominal fee is to cover event expenses.
Click here to register.
WORKSHOP LOCATION
Spring House Innovation Park
727 Norristown Rd., Building 1
Lower Gwynedd Township, PA 19002
LOGISTICS
Easy access to major international airports, SEPTA regional train stations, and large metropolitan areas.
Download a copy of the Workshop logistics for hotel recommendations and directions HERE.
BACKGROUND
Bioanalysis of ADCs is uniquely challenging, requiring multiple assays (e.g., total antibody, conjugated antibody, free payload, metabolites, immunogenicity) across preclinical and clinical phases. Current industry practice often “measures everything,” resulting in high costs, excessive time demands, and large sample volumes. The IQ Consortium’s Drug Conjugates Working Group, co-chaired by Faye Vazvaei-Smith (Merck & Co. Inc.) and Wenkui Li (Novartis) is driving consensus on best practices to make ADC bioanalysis more efficient and fit-for-purpose.
PURPOSE OF WORKSHOP
Save the date to join us for a full-day IQ Consortium workshop focused on harmonizing and streamlining bioanalytical practices for Antibody-Drug Conjugates (ADCs), reducing unnecessary complexity and resource use while maintaining scientific rigor and patient safety.
GOAL OF WORKSHOP
Develop clear consensus recommendations on which ADC constituent(s) should be measured—and when—enabling efficient fit-for-purpose bioanalysis across the stages of drug development. This includes alignment on:
- Which analyte(s)/assessment (e.g., total antibody, conjugated antibody, free payload, conjugated payload/metabolites/immunogenicity) are essential at each phase (preclinical, Phase I, pivotal studies, post-approval).
- When there is scientifical justification to start or stop measuring specific constituents.
- How to balance regulatory expectations with operational efficiency.
HIGHLIGHTS
- KEYNOTE: Antibody Drug Conjugates (ADC) As Therapeutic Options: History, Resurgence, Clinical Pharmacology Opportunities and Challenges
- IQ Survey results: Current practices and opportunities for streamlining
- FDA participation: Regulatory experience
- Breakout sessions: Practical guidance for “what to measure, when”
- Consensus-building: Drafting the IQ playbook for ADC bioanalysis
Who Should Attend?
-
- Bioanalytical, PK, and modeling scientists
- Clinical pharmacology professionals
- Regulatory affairs professionals
- Program strategists and operational leads
Why Attend?
-
- Shape industry best practices for ADC bioanalysis
- Collaborate with leading experts from IQ TALG, CPLG, Statistics LGs, and regulatory agencies (FDA invited)
- Contribute to a decision framework that reduces unnecessary complexity and resource use
- Engage in breakout sessions on assay strategy, PK/ER modeling, immunogenicity, and operational streamlining
QUESTIONS
Contact the IQ Secretariat:
✉ [email protected] | 📞 +1 (202) 230-5607
Share LinkedIn Announcement
